Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

30 articles from the last 7 days

ResearchRSS3 days ago

Long-term air pollution exposure shows no clear link to ALS in UK study

A large study in the UK followed over 500,000 people for about 10 years and found that breathing polluted air for a long time does not appear to increase the risk of getting ALS, a disease that affects nerve cells that control muscles. Fewer than 1,000 people in the study developed ALS during the study period. This suggests that air pollution may not be an important risk factor for developing ALS.

WHY IT MATTERSIf you have ALS or are worried about developing it, this study suggests that long-term air pollution exposure is unlikely to be a major cause, which may help reduce anxiety about environmental risk factors you cannot easily control.
Good to knowamyotrophic lateral sclerosisRead →
ResearchRSS3 days ago

Spontaneous mutations may underlie some sporadic ALS cases

Scientists discovered that some people with ALS (a disease that affects nerve cells controlling muscles) may develop the condition from new mutations that happen by chance in their nerve cells, rather than inheriting the mutation from their parents. This is different from inherited ALS cases where a parent passes down a faulty gene. This finding suggests there are multiple ways ALS can develop, which could help doctors better understand and treat the disease.

WHY IT MATTERSIf your ALS diagnosis is sporadic (not inherited), this research suggests your condition may have developed from random mutations in your nerve cells rather than a genetic predisposition, which could change how doctors approach your treatment and genetic counseling.
Good to knowAmyotrophic Lateral Sclerosis (ALS)Read →
ResearchRSS3 days ago

Antipsychotic drug may help treat SMA symptoms, research shows

Scientists found that haloperidol, a medication normally used to treat psychiatric conditions, may help treat spinal muscular atrophy (SMA) by increasing levels of a protein called SMN that is missing or low in SMA patients. In laboratory tests with mouse cells and human patient cells, haloperidol helped nerve cells survive longer, reduced harmful inflammation, and improved movement. This suggests haloperidol could potentially be used alongside or instead of current SMA treatments.

WHY IT MATTERSIf haloperidol proves effective in human trials, SMA patients could potentially benefit from a medication that already exists and is FDA-approved, potentially offering a faster path to treatment than developing entirely new drugs.
💬 Ask your doctorspinal muscular atrophyRead →
ResearchRSS3 days ago

Early nerve-muscle connection flaws set stage for SMA damage

Scientists studied how spinal muscular atrophy (SMA) damages the connections between nerves and muscles. They found that in people with SMA, these nerve-muscle connections don't develop properly right after birth, making them weak and unable to work well before nerve cells start dying. This early problem may be an important part of how SMA causes muscle weakness.

WHY IT MATTERSUnderstanding that nerve-muscle connection problems happen early in SMA—before nerve cell loss—could lead to new treatments that target this early stage rather than only treating later damage.
Good to knowSpinal Muscular Atrophy (SMA)Read →
ResearchPUBMED3 days ago

Characteristics of Patients with Myasthenia Gravis in the French Rare Disease Registry.

Researchers in France studied a group of patients with myasthenia gravis (a rare disease where muscles become weak and tired easily) who were treated at special centers between 2007 and 2021. They collected information about these patients' backgrounds, how their disease developed, and how long they lived. This study helps doctors understand more about this disease and how to care for patients better.

WHY IT MATTERSThis registry data provides real-world evidence about myasthenia gravis outcomes and patient characteristics in France, which can help identify gaps in care and inform treatment guidelines for MG patients across Europe.
Good to knowMyasthenia GravisRead →
ResearchPUBMED3 days ago

Can German Health Insurance Claims Data Fill Information Gaps in Rare Chronic Diseases: Use Case of Haemophilia A.

Researchers in Germany studied health insurance records from 2017-2019 to understand how hemophilia A (a bleeding disorder) affects patients and how much it costs to treat. They found 257 patients with hemophilia A and grouped them by severity—mild, moderate, or severe—based on how much clotting medicine they needed. This study shows that insurance data can help doctors and researchers learn more about rare diseases like hemophilia A.

WHY IT MATTERSIf you have hemophilia A in Germany, this research demonstrates that your health insurance claims data can be used to better understand disease patterns, treatment costs, and care gaps—potentially leading to improved healthcare planning and resource allocation for your condition.
Good to knowHemophilia ARead →
ResearchPUBMED4 days ago

Linear Interstitial Keratitis - A Retrospective Chart Review of a Rare Entity.

Linear interstitial keratitis (LIK) is a very rare eye condition where a thin line of cloudiness forms in the clear part of the eye (the cornea). This study looked at 6 patients with this condition to better understand what it looks like, how doctors can diagnose it, and what treatments work best. The researchers found that the cloudy line usually appears near the edge of the cornea and can be seen clearly with special eye imaging tools.

WHY IT MATTERSThis is the largest study to date on linear interstitial keratitis, providing eye doctors with new guidance on diagnosis and treatment options for a condition that previously had no agreed-upon management approach.
💬 Ask your doctorLinear Interstitial KeratitisInterstitial KeratitisRead →
ResearchPUBMED5 days ago

'If You Don't Fight for Yourself, No One Else Will': An In-Depth Interpretative Phenomenological Analysis of Rare Disorder Care Advocacy in Aotearoa New Zealand.

Researchers in New Zealand interviewed 15 people with rare diseases and their caregivers to understand what it's like to get diagnosed and treated. They found that patients often have to fight hard to get answers and support because doctors don't know much about rare diseases. The study shows that people with rare diseases face similar challenges, even though their specific conditions are very different.

WHY IT MATTERSThis research directly documents the real-world barriers that rare disease patients face in accessing diagnosis and care in New Zealand, providing evidence that could help healthcare systems improve support for the estimated 300 million people worldwide living with rare disorders.
Good to knowRead →
ResearchBIORXIV6 days ago

Preprint: Plasma proteomics identifies early markers of endothelial and inflammatory activation associated with dengue disease severity in children

Researchers studied blood samples from children with dengue virus infection to find early warning signs that could predict who will develop severe disease. By analyzing proteins in the blood, they identified markers related to inflammation and blood vessel damage that appear in children who get sicker. This discovery could help doctors quickly identify which children need more intensive care.

WHY IT MATTERSIf validated, these protein markers could enable doctors to predict dengue severity within hours of diagnosis in children, allowing earlier intervention before complications like hemorrhagic fever or shock develop.
👁 Watch this spacedengue feverdengue hemorrhagic feverdengue shock syndromeRead →
ResearchBIORXIV6 days ago

Preprint: Blood-based RNA-Seq of 5412 individuals with rare disease identifies new candidate diagnoses in the National Genomic Research Library

Researchers analyzed blood samples from over 5,400 people with rare genetic diseases to see if a test called RNA-Seq could help find the genetic cause of their conditions. They found that this blood test works better for some diseases than others, and they used special computer programs to spot unusual gene activity patterns that might explain why people got sick. This study shows that blood tests could be a useful tool to help diagnose rare diseases alongside other genetic tests.

WHY IT MATTERSIf you have an undiagnosed rare disease, this research suggests blood-based RNA testing could help identify the genetic cause—potentially leading to a diagnosis after years of searching.
Good to knowRead →
← PreviousPage 2 of 2

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases